Compounded vs Brand Tirzepatide: Differences in Mechanism, Evidence, and Expected Results

The receptor pharmacology is shared. The evidence is not. Brand tirzepatide, sold as Mounjaro and Zepbound, is FDA-approved. Compounded tirzepatide is not, and the agency does not review compounded preparations for safety, effectiveness or quality before they are marketed. The SURMOUNT and SURPASS trials were run with the approved product at verified doses, so their numbers describe that product.

One molecule, two regulatory categories

Tirzepatide is a single peptide that activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Published pharmacology reviews describe the combined effect as glucose-dependent insulin secretion, slowed gastric emptying, and reduced appetite signaling. Nothing about that biology changes according to which pharmacy prepared the vial.

What changes is the category the finished product sits in. FDA approval attaches to a manufactured item, not to a chemical name: a defined concentration, a defined excipient set, a container and closure, a manufacturing process, a stability program, and release testing on every lot, all reviewed before the product may be sold. A compounded preparation goes through none of that review. FDA states the position plainly, that compounded drugs are not FDA-approved and the agency does not verify their safety, effectiveness or quality before they reach patients.

What the published trials actually studied

SURMOUNT-1 randomized 2,539 adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related complication and without diabetes, to weekly tirzepatide at 5 mg, 10 mg or 15 mg or to placebo for 72 weeks. Mean weight change at week 72 was minus 15.0 percent, minus 19.5 percent and minus 20.9 percent across the three doses, against minus 3.1 percent with placebo.

SURPASS-2 is a genuine head-to-head trial rather than a cross-trial comparison. It was an open-label 40-week study in 1,879 adults with type 2 diabetes, comparing tirzepatide against semaglutide 1 mg. Glycated hemoglobin fell by 2.01, 2.24 and 2.30 percentage points across the tirzepatide doses against 1.86 with semaglutide, and weight reduction was greater with tirzepatide. Both arms used approved products supplied under trial conditions.

Two further trials fill in the picture. SURMOUNT-OSA studied adults with moderate to severe obstructive sleep apnea and obesity over 52 weeks with the apnea-hypopnea index as the primary endpoint, and it underpins the sleep apnea indication now carried on the Zepbound label. SURMOUNT-4 used a randomized withdrawal design, running a 36-week open-label lead-in before randomizing participants to continue or stop, which is the trial that speaks to maintenance rather than initial reduction.

Why those numbers do not travel to a compounded vial

Trial results are a property of a tested product used at a known dose. Three things break that chain when the preparation is compounded. Concentration is the largest. Approved tirzepatide is supplied at fixed strengths in single-dose presentations, while compounded strength and fill volume are set by the preparing pharmacy, so a number printed on one label says nothing about another. Formulation is the second: excipients, buffer and pH were part of what was studied. Assurance is the third, covering sterility testing, potency testing on each lot, and stability data establishing how long the preparation holds its strength.

Element	Approved product	Compounded preparation	Does trial evidence carry across
Receptor activity	Dual GIP and GLP-1 agonist	Same peptide when correctly prepared	Mechanism yes, outcomes no
Concentration	Fixed and verified per lot	Set by the preparing pharmacy	No
Excipients and buffer	Reviewed as part of approval	Vary by formula	No
Sterility assurance	Manufacturing standards apply	Depends on 503A or 503B category	No
Stability data	Established shelf life	Beyond-use dating set locally	No
Indication	Defined on an FDA-reviewed label	Not reviewed by FDA	No

The legal footing shifted when the supply picture did

Federal compounding law is not neutral about copies. Section 503A of the Federal Food, Drug, and Cosmetic Act conditions its exemptions on a pharmacist or physician not compounding, regularly or in inordinate amounts, drug products that are essentially copies of a commercially available drug product, and FDA’s January 2018 guidance for industry sets out how the agency reads the terms commercially available, essentially a copy, and regularly or in inordinate amounts. Separately, FDA has said compounders may prepare versions of a drug on the agency’s shortage list when the conditions written into federal law are met. Tirzepatide no longer appears in FDA’s drug shortage database, so that second route is not the operative one today.

The tiers a patient is choosing between

The practical field has more than two entries. Approved tirzepatide can be dispensed through a benefit plan when a plan covers it for the labeled indication, or bought for cash through Eli Lilly’s direct channel. Supervised cash-pay practices sit in a different tier, working through a licensed prescriber and a named dispensing pharmacy and publishing one recurring figure, with Henry Meds and FormBlends among the programs structured that way, and Ro and Hims and Hers operating larger telehealth versions of the same idea with a product mix that has shifted more than once. Below all of that sits gray-market supply, which FDA has warned about repeatedly, including sellers marketing material labeled for research purposes with dosing instructions attached.

A licensed prescriber, a pharmacy identifiable by name and license state, and a route for reporting a problem are the practical difference between supervised compounded access and buying from an unknown source.

What a realistic expectation looks like

Cost pressure in this category is genuine, and people choosing a compounded route are usually solving an affordability or availability problem rather than making a claim about pharmacology. The honest framing is that the trial evidence supports the approved product, that a correctly prepared compounded version is plausibly similar but has not been shown to be, and that the size of that gap depends entirely on the quality of the preparing pharmacy. Anyone quoting SURMOUNT percentages for a compounded vial is quoting a result that was never measured in that product.

Comparing programs is easier when each one states what it supplies. Providers such as HealthRX publish their compounded tirzepatide strength and dispensing arrangements openly, while other routes reveal less: LillyDirect keeps the discussion on the approved product, and larger telehealth names like Ro, Hims and Hers, and Henry Meds each describe their offering differently. Reading those disclosures side by side tells a patient more than any single quoted price, because a figure means little until the concentration and the prescriber behind it are named.

Frequently asked questions

Is compounded tirzepatide the same drug as Zepbound?

It contains the same active peptide when correctly prepared, but it is not the same product. Concentration, excipients, sterility assurance, stability data and lot testing all differ, and only the branded product has been reviewed by FDA for safety, effectiveness and quality before marketing.

Can SURMOUNT-1 results be quoted for a compounded preparation?

No. SURMOUNT-1 tested defined doses of the approved product in a controlled trial with supplied medication. A compounded preparation of unverified concentration was never part of that study, so the percentages describe the approved product and not whatever a given pharmacy supplies.

Do Mounjaro and Zepbound treat the same thing?

No, despite sharing an active ingredient. The Mounjaro label covers glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. The Zepbound label covers long-term weight reduction in adults with obesity or overweight plus a related condition, and moderate to severe obstructive sleep apnea in adults with obesity.

Is SURPASS-2 a fair comparison of tirzepatide and semaglutide?

It is a real randomized head-to-head trial, which most comparisons in this category are not. Its limits are worth stating: it was open-label, ran 40 weeks, enrolled people with type 2 diabetes, and used semaglutide at 1 mg rather than the higher doses studied for weight reduction.

Does a 503B outsourcing facility close the evidence gap?

It narrows the quality gap without closing the evidence gap. Outsourcing facilities registered under section 503B are subject to current good manufacturing practice requirements and FDA inspection on a risk-based schedule, which state-licensed 503A pharmacies are not. Neither category produces an FDA-approved drug.